{"gene":"SALL4","run_date":"2026-06-10T07:46:29","timeline":{"discoveries":[{"year":2006,"finding":"SALL4 binds to the highly conserved distal enhancer region of the Pou5f1 (Oct4) gene and transcriptionally activates Pou5f1 expression in vivo and in vitro; siRNA knockdown of Sall4 in mouse zygotes reduced both Sall4 and Oct4 mRNAs and expanded Cdx2 expression into the inner cell mass, establishing SALL4 as a direct transcriptional activator of Oct4.","method":"Chromatin immunoprecipitation (ChIP), luciferase reporter assay, siRNA microinjection into mouse zygotes, in vitro transcription assays","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ChIP, reporter assay, in vivo siRNA), replicated across ES cell and embryo contexts","pmids":["16980957"],"is_preprint":false},{"year":2006,"finding":"SALL4 physically interacts with NANOG in embryonic stem cells (identified by affinity purification/MS, confirmed by Co-IP and GST pulldown); SALL4 and NANOG co-occupy each other's enhancer regions and many shared genomic loci, forming a positive autoregulatory circuit that maintains ES cell-specific enhancer activity.","method":"Affinity purification coupled to LC-MS/MS, co-immunoprecipitation, GST pulldown, chromatin immunoprecipitation (ChIP), RNAi knockdown with luciferase enhancer activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP confirmed by GST pulldown and ChIP, multiple orthogonal methods in single study","pmids":["16840789"],"is_preprint":false},{"year":2009,"finding":"SALL4 associates with the Mi-2/NuRD (Nucleosome Remodeling and Deacetylase) complex, identified by tandem mass spectrometry of SALL4 immunocomplexes; this complex carries HDAC activity. SALL4 directly represses PTEN and SALL1 transcription through co-occupancy of their promoters with NuRD components, as confirmed by ChIP.","method":"Tandem mass spectrometry of SALL4 immunocomplexes, co-immunoprecipitation, HDAC activity assay, ChIP, qRT-PCR, SALL4 transgenic mouse model","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — MS-identified complex confirmed by Co-IP and HDAC activity assay, ChIP validation of target gene occupancy, in vivo transgenic confirmation","pmids":["19440552"],"is_preprint":false},{"year":2007,"finding":"SALL4 directly binds the Bmi-1 promoter and transcriptionally activates Bmi-1 expression in a dose-dependent manner; SALL4-bound Bmi-1 promoter regions show elevated H3-K4 trimethylation and H3-K79 dimethylation, providing an epigenetic mechanism for SALL4-mediated Bmi-1 upregulation.","method":"Luciferase reporter assay with promoter deletion constructs, ChIP from myeloid stem cells, siRNA knockdown in HL-60 cells, SALL4 transgenic mice, gene targeting (heterozygous deletion)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, reporter assay, genetic deletion, and transgenic mouse model all converge on same conclusion","pmids":["17557835"],"is_preprint":false},{"year":2011,"finding":"SALL4 represses gene expression through direct interaction with DNA methyltransferases (DNMT1, DNMT3A, DNMT3B); co-IP and DNMT enzyme activity assays confirmed physical interaction; SALL4 isoforms co-occupy their own promoter with DNMTs, and SALL4 overexpression increases CpG island methylation of silenced target genes (including PTEN). HDAC inhibition and DNA methylation inhibition synergistically block SALL4-mediated repression.","method":"Co-immunoprecipitation, DNMT enzymatic activity assay, ChIP, luciferase reporter assay, bisulfite sequencing/CpG methylation analysis, pharmacological inhibitors (VPA, 5-azaC)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — biochemical Co-IP + enzyme activity assay + ChIP + methylation analysis, multiple cell types tested","pmids":["22128185"],"is_preprint":false},{"year":2013,"finding":"Blocking SALL4–NuRD corepressor interactions (using a peptide targeting SALL4's N-terminal region) releases repression of PTEN and inhibits tumor formation in xenograft models; SALL4 loss-of-function studies confirmed its critical role in hepatocellular carcinoma cell survival and tumorigenicity.","method":"Loss-of-function (RNAi), in vivo xenograft assays, peptide inhibitor blocking SALL4–NuRD interaction, gene expression analysis","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic rescue experiment (peptide disruption of SALL4-NuRD) with in vivo xenograft validation, replicated by structural study (PMID 29976840)","pmids":["23758232"],"is_preprint":false},{"year":2018,"finding":"Crystal structure of SALL4 N-terminal peptide (residues 1–12) complexed with RBBp4 (NuRD chaperone subunit) resolved at 2.7 Å; a therapeutic peptide (FFW) designed from this structure disrupts the SALL4–NuRD interaction with 23 nM affinity, converting SALL4 from a dual repressor-activator to a singular activator mode and inhibiting xenograft tumor growth by 85%.","method":"X-ray crystallography, peptide design with systematic truncation/substitution, transcriptome profiling, in vivo xenograft tumor model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional validation by in vivo xenograft and transcriptome profiling","pmids":["29976840"],"is_preprint":false},{"year":2013,"finding":"SALL4 directly binds to the HOXA9 promoter in leukemic cells; SALL4 overexpression increases activating histone marks (H3-K4me3, H3-K79me2) at the HOXA9 promoter; SALL4 physically interacts with MLL and co-occupies the HOXA9 promoter with MLL, defining a SALL4/MLL/HOXA9 pathway in myeloid leukemogenesis.","method":"ChIP, co-immunoprecipitation (SALL4–MLL interaction), siRNA knockdown, in vitro replating assay, in vivo AML transplantation model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP for SALL4-MLL, ChIP for co-occupancy, both in vitro and in vivo functional validation","pmids":["24051379"],"is_preprint":false},{"year":2016,"finding":"SALL4 is dispensable for mouse ES cell pluripotency maintenance; instead, SALL4 functions as an enhancer-binding protein that prevents precocious activation of the neural gene expression program. Although a proportion of SALL4 protein physically associates with NuRD, SALL4 neither recruits NuRD to chromatin nor regulates transcription via NuRD; free SALL4 protein regulates transcription independently of NuRD.","method":"Conditional Sall4 knockout in ES cells, genome-wide enhancer binding (ChIP-seq), quantitative proteomics (MS) of NuRD interaction, transcriptome analysis (RNA-seq), differentiation assays","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP-seq, quantitative MS, and KO with transcriptome, single lab but multiple orthogonal methods; contradicts some NuRD-recruitment claims (PMID 19440552)","pmids":["27471257"],"is_preprint":false},{"year":2021,"finding":"SALL4 binds AT-rich genomic motifs via a specific zinc-finger cluster; mutation of this AT-binding domain drastically reduces SALL4 genome occupancy and prematurely upregulates genes in proportion to their AT content, causing precocious neural differentiation. This AT-binding zinc-finger cluster is functionally essential, as its inactivation mimics full Sall4 null phenotypes including embryonic lethality; deletion of two other zinc-finger clusters was phenotypically neutral.","method":"Genome-wide screen for AT-binding proteins, domain-specific mutagenesis, ChIP-seq, RNA-seq, mouse knockout (domain-specific), embryonic lethality assessment","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vivo mutagenesis with embryonic lethality, ChIP-seq and transcriptome, multiple orthogonal methods revealing precise mechanistic domain","pmids":["33406384"],"is_preprint":false},{"year":2006,"finding":"SALL4 is directly activated by TCF/LEF transcription factors in the canonical Wnt signaling pathway; a consensus TCF/LEF-binding site within a 31 bp minimal SALL4 promoter region is required, as mutation of this site reduces promoter activation by LEF1 and TCF4E.","method":"SALL4 promoter cloning, luciferase reporter assay, site-directed mutagenesis of TCF/LEF binding site, transient transfection with LEF1 and TCF4E","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — reporter assay with mutagenesis in single lab, no in vivo ChIP confirmation of TCF/LEF occupancy","pmids":["16899215"],"is_preprint":false},{"year":2005,"finding":"Tbx5 regulates Sall4 expression in developing mouse forelimb and heart; Tbx5 and Sall4 interact both positively and negatively in a feed-forward circuit to regulate anterior forelimb and heart patterning; Sall4 heterozygous gene-trap mice exhibit limb and heart defects modeling human Okihiro/Holt-Oram syndromes.","method":"Mouse genetics (Sall4 gene-trap heterozygous), in situ hybridization, compound mutant analysis (epistasis), expression analysis in Tbx5 mutants","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with multiple mutant combinations, in vivo phenotypic analysis, expression downstream relationship established","pmids":["16380715"],"is_preprint":false},{"year":2012,"finding":"In differentiating spermatogonial progenitor cells (SPCs), SALL4 physically interacts with PLZF; SALL4 sequesters PLZF to non-cognate chromatin domains to derepress Kit expression (a PLZF-repressed differentiation target); conversely, PLZF displaces SALL4 from cognate chromatin to induce Sall1 expression, creating a mutual antagonism that defines the self-renewal vs. differentiation balance.","method":"Co-immunoprecipitation (SALL4-PLZF interaction), ChIP, genetic knockout/overexpression in SPCs, Kit expression analysis","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP confirmed interaction, ChIP established chromatin displacement mechanism, genetic models validated functional outcome","pmids":["22385656"],"is_preprint":false},{"year":2008,"finding":"Sall4 is cell-autonomously required for development of epiblast and primitive endoderm from the inner cell mass; Sall4-deficient blastocysts cannot give rise to embryonic or extraembryonic endoderm stem cell lines. Trophoblast lineage development is unaffected by Sall4 loss.","method":"Conditional mouse knockout (Sall4-null), blastocyst culture and stem cell line derivation, chimera analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic null mouse with cell-autonomous rescue experiment and lineage-specific phenotype","pmids":["17060609"],"is_preprint":false},{"year":2008,"finding":"Sall4 regulates distinct gene sets and transcriptional circuits in embryonic stem cells (ESCs) versus extraembryonic endoderm (XEN) cells; in ESCs, Sall4 forms an interconnected autoregulatory network with Oct4, Sox2, and Nanog; in XEN cells, Sall4 regulates Gata4, Gata6, Sox7, and Sox17. Depletion of Sall4 in XEN cells disrupts self-renewal and induces differentiation.","method":"Genome-wide ChIP-chip, siRNA knockdown in both ESC and XEN cells, gene expression profiling, differentiation assays","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP in two cell types, functional KD with differentiation phenotype, multiple orthogonal methods","pmids":["18804426"],"is_preprint":false},{"year":2016,"finding":"Maternal SALL4 is required for epigenetic maturation of mouse oocytes; maternal-specific Sall4 deletion (via CRISPR/Cas9) causes oocyte developmental arrest at the germinal vesicle stage with non-surrounded nucleus and prevents meiosis resumption. Loss of maternal Sall4 causes failure of DNA methylation establishment and dysregulation of H3K4me3 and H3K27me3 modifications by altering expression of histone demethylases Kdm5b, Kdm6a, and Kdm6b.","method":"Maternal-specific CRISPR/Cas9 knockout, bisulfite sequencing (DNA methylation), ChIP for histone marks, gene expression analysis (qRT-PCR)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with mechanistic histone and DNA methylation profiling, multiple orthogonal methods","pmids":["28031467"],"is_preprint":false},{"year":2017,"finding":"SALL4 associates with the NuRD co-repressor complex in undifferentiated spermatogonia and represses tumor suppressor genes Foxl1 and Dusp4; aberrant Foxl1 activation inhibits undifferentiated cell growth and survival, while DUSP4 suppresses self-renewal pathways. Inducible knockout showed short-term integrity of differentiating spermatogonia requires SALL4, while long-term undifferentiated spermatogonial function and stem cell-driven regeneration also depend on SALL4.","method":"Inducible knockout mouse model, Co-IP (SALL4-NuRD), ChIP, gene expression analysis, functional regeneration assays","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible KO with NuRD Co-IP and ChIP validation of target gene repression, in vivo regeneration assay","pmids":["28867346"],"is_preprint":false},{"year":2015,"finding":"SALL4 directly associates with retinoic acid receptor α (RARα) and modulates ATRA target gene expression; SALL4 recruits lysine-specific histone demethylase 1 (LSD1/KDM1A) to target genes and alters their histone methylation status, thereby blocking ATRA-induced AML differentiation. Co-inhibition of LSD1 and SALL4 with ATRA produced the strongest anti-AML effect.","method":"Co-immunoprecipitation (SALL4-RARα and SALL4-LSD1), ChIP for histone methylation, siRNA knockdown, SALL4 overexpression, flow cytometry differentiation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP for two distinct interaction partners (RARα and LSD1), ChIP for histone marks, functional differentiation assays","pmids":["25737450"],"is_preprint":false},{"year":2017,"finding":"In MLL-AF9 leukemia, SALL4 physically interacts with DOT1L (H3K79 methyltransferase) and LSD1/KDM1A, co-occupies MLL-AF9 target gene promoters, and regulates H3K79me2/3 and H3K4me3 marks at those promoters. SALL4 loss in MLL-AF9-transformed cells induced apoptosis and G1 cell cycle arrest; normal hematopoiesis is unaffected by Sall4 deletion.","method":"ChIP-seq, Co-immunoprecipitation (SALL4-DOT1L, SALL4-LSD1), mRNA microarray, inducible Cre knockout, apoptosis/cell cycle assays, in vivo leukemia transplantation","journal":"Journal of hematology & oncology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq, Co-IP for two chromatin modifiers, inducible in vivo KO with both in vitro and in vivo phenotyping","pmids":["28974232"],"is_preprint":false},{"year":2017,"finding":"SALL4 promotes open chromatin by recruiting ubiquitin E3 ligase CUL4B to HP1α, thereby destabilizing HP1α (heterochromatin protein 1α). This mechanism upregulates Glut1 expression and promotes glycolysis; impaired DNA damage response (DDR) in SALL4-deficient cells can be rescued by restoring Glut1 expression, linking SALL4-HP1α-Glut1 axis to DDR and chemoresistance.","method":"Co-immunoprecipitation (SALL4-CUL4B-HP1α), chromatin accessibility assay, glucose uptake/glycolysis assays, rescue experiments with Glut1","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP identifies ternary complex, functional rescue experiments, but single lab with limited orthogonal validation","pmids":["28759035"],"is_preprint":false},{"year":2019,"finding":"SALL4 binds to the promoter of miR-146a-5p and directly controls its expression in HCC exosomes; the SALL4/miR-146a-5p regulatory axis drives M2 macrophage polarization and T cell exhaustion (via induction of PD-1 and CTLA-4 on T cells). Blocking this axis reduced inhibitory receptor expression on T cells and delayed HCC progression in a mouse model.","method":"ChIP (SALL4 binding to miR-146a-5p promoter), exosome isolation and miRNA quantification, macrophage polarization assays, T cell functional assays, in vivo DEN/CCL4-induced HCC mouse model","journal":"Oncoimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP confirms direct binding at miR-146a-5p promoter, functional in vivo validation, single lab","pmids":["31143524"],"is_preprint":false},{"year":2018,"finding":"HBV-induced STAT3 activation drives re-expression of SALL4 in adult hepatocytes; SALL4 then occupies the miR-200c promoter to suppress miR-200c transcription, which in turn de-represses PD-L1 (CD274), promoting T cell exhaustion. The HBV-pSTAT3-SALL4-miR-200c-PD-L1 axis was confirmed by ChIP and miR-200c 3'-UTR reporter assays.","method":"ChIP (SALL4 binding to miR-200c promoter), luciferase 3'-UTR reporter assay, overexpression/knockdown of pathway components, T cell exhaustion assays, clinical HCC specimen correlation","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and reporter assays establish direct promoter binding, functional T cell assays, single lab","pmids":["29593314"],"is_preprint":false},{"year":2016,"finding":"DNA demethylation of CpG sites downstream of the SALL4 transcriptional start site enables binding of OCT4 and STAT3 at those sites, recruitment of chromatin remodeling complex BRG1/BAF, and enhanced RNA polymerase II elongation through the SALL4 locus, thereby driving SALL4 re-expression in HBV-related HCC. BRG1 knockdown reduced SALL4 expression, while BRG1 overexpression increased it.","method":"Bisulfite sequencing PCR, ChIP (RNA Pol II, OCT4, STAT3, BRG1 occupancy), sequential ChIP (co-occupancy), BRG1 knockdown/overexpression","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple ChIP assays including sequential ChIP for co-occupancy, functional BRG1 manipulation, single lab","pmids":["27797380"],"is_preprint":false},{"year":2015,"finding":"Sall4 is required for mouse primordial germ cell (PGC) specification; conditional inactivation of Sall4 during PGC specification caused somatic program gene derepression (Hoxa1, Hoxb1) in PGC progenitors without impairing stem cell program activation. Sall4 was shown to bind somatic cell program gene loci (occupied by Prdm1 in embryonic carcinoma cells), and since Sall4 and Prdm1 associate with the HDAC repressor complex, Sall4 likely suppresses the somatic program by recruiting this repressor complex with Prdm1.","method":"Conditional Sall4 knockout, qRT-PCR for somatic program genes, ChIP (Sall4 binding at Hoxa1/Hoxb1 loci in differentiated ESCs), apoptosis assays","journal":"Stem cells (Dayton, Ohio)","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — conditional KO with ChIP validation in ESC system, in vivo PGC counting; mechanistic link to Prdm1/HDAC is inferred from ChIP context, single lab","pmids":["25263278"],"is_preprint":false},{"year":2019,"finding":"Sall4 promotes WNT/β-catenin signaling to maintain neuromesodermal progenitors (NMPs) and control their differentiation balance toward mesodermal versus neural fates during mouse body elongation; SALL4 ChIP-seq identified direct target genes in both mesodermal and neural compartments; Sall4 deletion caused body/tail truncation due to NMP depletion at the trunk-to-tail transition.","method":"Conditional Sall4 knockout (TCre), RNA-seq, SALL4 ChIP-seq, WNT/β-catenin signaling reporters, histological and molecular phenotype analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq combined with RNA-seq and conditional KO, multiple orthogonal methods, in vivo embryonic analysis","pmids":["31235634"],"is_preprint":false},{"year":2016,"finding":"In undifferentiated spermatogonia, SALL4 preferentially binds gene introns (while PLZF binds gene promoters); SALL4-bound sites contain motifs for the differentiation factor DMRT1. PLZF/SALL4 shared sites predominantly contain only PLZF motifs, indicating non-autonomous binding. Both PLZF- and SALL4-unique target genes involved in SSC self-renewal and differentiation are suppressed following their respective knockdown.","method":"ChIP-seq in THY1+ spermatogonia, motif analysis, siRNA knockdown followed by mRNA expression profiling","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq with motif analysis and functional KD in primary cells, single lab but comprehensive approach","pmids":["27068105"],"is_preprint":false},{"year":2023,"finding":"During somatic cell reprogramming, the NuRD complex participates in closing open chromatin in an early phase; SALL4 (but not Jdp2, Glis1, or Esrrb) is indispensable for recruiting endogenous NuRD components. Mutation or deletion of SALL4's N-terminal NuRD-interacting motif abolishes reprogramming efficiency; grafting this motif onto Jdp2 partially rescues reprogramming, establishing the SALL4–NuRD axis as critical for chromatin closing during cell fate transition.","method":"ATAC-seq (chromatin accessibility), Co-IP (SALL4-NuRD), domain deletion/mutation, motif grafting rescue experiment, iPSC reprogramming efficiency assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ATAC-seq mechanistic chromatin data, domain-swap rescue experiment, Co-IP, multiple orthogonal methods","pmids":["37208322"],"is_preprint":false},{"year":2018,"finding":"SALL4 promotes gastric cancer metastasis by directly binding to the TGF-β1 gene promoter and activating its transcription, thereby activating TGF-β/SMAD signaling and inducing EMT; TGF-β1 knockdown reversed SALL4-mediated promotion of cancer cell motility.","method":"ChIP assay (SALL4 binding at TGF-β1 promoter), luciferase reporter assay, microarray, siRNA knockdown, in vivo peritoneal metastasis model","journal":"Cancer management and research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and luciferase confirm direct promoter binding; rescue experiment with TGF-β1 KD validates epistasis; single lab","pmids":["30349378"],"is_preprint":false},{"year":2016,"finding":"SALL4 binds the CD44 promoter region and transcriptionally activates CD44 expression; CD44 overexpression rescued SALL4 knockdown-mediated inhibition of gastric cancer cell proliferation, migration, and invasion in vitro and in vivo, establishing CD44 as a functional downstream effector of SALL4.","method":"ChIP, luciferase reporter assay, shRNA knockdown with tetracycline-inducible system, CD44 rescue experiment, in vivo xenograft model","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and reporter confirm direct binding; epistasis rescue validates mechanism; single lab","pmids":["27819668"],"is_preprint":false},{"year":2020,"finding":"SALL4 directly binds the HK-2 (hexokinase II) gene promoter and activates its transcription; HK-2 knockdown abrogated SALL4-promoted glycolysis and reversed SALL4-driven gastric cancer cell proliferation, migration, and invasion, establishing HK-2 as a downstream effector of SALL4-mediated Warburg effect.","method":"ChIP, luciferase reporter assay, microarray, glycolysis assays (glucose uptake, lactate, ATP, hexokinase activity), HK-2 rescue experiment, in vivo xenograft and peritoneal metastasis models","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and reporter confirm direct SALL4 binding at HK-2 promoter; epistasis rescue with multiple functional readouts; single lab","pmids":["32489324"],"is_preprint":false},{"year":2013,"finding":"SALL4 directly binds the c-Myc promoter region in endometrial cancer cells; SALL4 knockdown decreases c-Myc expression at both mRNA and protein levels, and SALL4 overexpression increases c-Myc, establishing c-Myc as a direct transcriptional target of SALL4 in endometrial tumorigenesis.","method":"ChIP, siRNA knockdown, SALL4 overexpression, qRT-PCR, Western blot, in vivo xenograft and metastasis models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP confirms direct promoter binding; gain/loss-of-function validates target regulation; single lab","pmids":["24336327"],"is_preprint":false},{"year":2013,"finding":"SALL4 suppresses CDH1 (E-cadherin) expression and positively regulates the CDH1 suppressor ZEB1 in basal-like breast cancer; SALL4 maintains cell dispersion by suppressing intercellular adhesion and cell motility after cell-cell interaction.","method":"shRNA knockdown, SALL4 overexpression, cell behavior analysis (adhesion, motility, dispersion assays), gene expression analysis","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — functional KD/OE with phenotypic readout, no direct ChIP for CDH1/ZEB1 promoters; single lab","pmids":["23954296"],"is_preprint":false},{"year":2018,"finding":"SALL4 upregulates KHDRBS3 (a splicing factor), which in turn modulates CD44 alternative splicing to produce a specific CD44 variant (CD44v lacking exons 8 and 9) that promotes cancer stemness and anoikis resistance in basal-like breast cancer.","method":"shRNA knockdown, gene overexpression, sphere formation assay, CD44 splicing isoform cloning and analysis, anoikis resistance assay","journal":"Cancer medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — functional epistasis via KD/rescue, splicing isoform cloning validates mechanism, single lab, no direct ChIP at KHDRBS3 promoter","pmids":["29356399"],"is_preprint":false},{"year":2021,"finding":"SALL4 negatively regulates melanoma invasiveness through interaction with HDAC2 and direct co-binding to a set of invasiveness gene loci; SALL4 loss or HDAC inhibition promotes an invasive gene expression signature while inhibition of histone acetylation partially reverts SALL4 loss-induced invasiveness.","method":"ChIP (SALL4 and HDAC2 co-binding), transcriptional profiling, SALL4 knockout in melanoma mouse model, HDAC inhibitor treatment, in vitro invasion assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP for co-binding, genetic KO in melanoma mouse model, pharmacological epistasis with HDAC inhibitor, multiple orthogonal methods","pmids":["34417458"],"is_preprint":false},{"year":2023,"finding":"SALL4 directly binds the promoters of VEGF-A, VEGF-B, and VEGF-C genes and activates their transcription, associated with increased H3K79 and H3K4 histone modifications; SALL4-regulated VEGF expression promotes gastric cancer angiogenesis by recruiting endothelial cells.","method":"ChIP, EMSA (electrophoretic mobility shift assay), luciferase reporter assay, SALL4 knockdown/knockout/overexpression, HUVEC functional assays (proliferation, migration, tube formation), in vivo xenograft","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and EMSA confirm direct DNA binding at VEGF promoters, functional endothelial cell assays validate downstream effect; single lab","pmids":["37525212"],"is_preprint":false},{"year":2017,"finding":"In Xenopus, sall4 (ortholog of mammalian SALL4) represses pou5f3 family gene expression (orthologs of Oct4/Pou5f1) in the neural plate; sall4 knockdown causes aberrant pou5f3 upregulation and defects in neural patterning, morphogenesis, and differentiation that phenocopy overexpression of pou5f3 genes.","method":"Morpholino knockdown of sall1/sall4, in situ hybridization, pou5f3 overexpression rescue/phenocopy experiments in Xenopus","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic epistasis via morpholino KD and pou5f3 overexpression phenocopy; Xenopus ortholog study, single lab","pmids":["28322736"],"is_preprint":false},{"year":2020,"finding":"Brg1 (BRG1/SMARCA4) directly binds the SALL4 promoter and enhances SALL4 transcription in HCC cells; miR-296-5p targets Brg1, thereby suppressing SALL4 expression and inhibiting HCC cancer stem cell stemness.","method":"ChIP (Brg1 binding to SALL4 promoter), luciferase reporter assay, miR-296-5p overexpression/knockdown, sphere formation assay, in vivo tumorigenesis in NOD/SCID mice","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP confirms Brg1 at SALL4 promoter; functional miRNA/Brg1/SALL4 axis validated; single lab","pmids":["32320856"],"is_preprint":false}],"current_model":"SALL4 is a zinc-finger transcription factor that maintains pluripotency and stem cell identity by binding AT-rich genomic enhancers (via a critical AT-binding zinc-finger cluster), directly activating key pluripotency genes (Oct4/Pou5f1, Nanog, Bmi-1, HoxA9, CD44, VEGF, c-Myc) and repressing tumor suppressors (PTEN, SALL1, Foxl1, Dusp4) through physical association with epigenetic co-repressor complexes including Mi-2/NuRD (via its N-terminal motif) and DNA methyltransferases; SALL4 also interacts with NANOG, PLZF, MLL, DOT1L, LSD1/KDM1A, RARα, CUL4B, and HDAC2 to modulate chromatin state at target loci, while its own expression is regulated upstream by TCF/LEF (Wnt signaling), BRG1-mediated chromatin remodeling at demethylated CpG sites, and STAT3 activation downstream of HBV infection."},"narrative":{"mechanistic_narrative":"SALL4 is a zinc-finger transcription factor that governs stem-cell identity and cell-fate transitions by binding AT-rich genomic enhancers through a specific zinc-finger cluster whose inactivation phenocopies the full Sall4-null state, including embryonic lethality and precocious neural differentiation [PMID:33406384]. In embryonic and extraembryonic stem cells SALL4 operates within an interconnected autoregulatory transcriptional network—physically associating with NANOG and co-occupying shared enhancers [PMID:16840789], directly activating Oct4/Pou5f1 [PMID:16980957], and engaging distinct circuits (Oct4/Sox2/Nanog versus Gata4/6/Sox7/17) depending on lineage context [PMID:18804426]—and is cell-autonomously required for epiblast and primitive endoderm formation from the inner cell mass [PMID:17060609]. SALL4 functions both as a transcriptional activator and as a repressor: its N-terminal motif recruits the Mi-2/NuRD nucleosome-remodeling and deacetylase complex to close chromatin and silence tumor-suppressor loci such as PTEN and SALL1 [PMID:19440552, PMID:37208322], and disruption of this SALL4–NuRD interface by a structurally-defined peptide releases PTEN repression, converts SALL4 to a singular activator, and blocks tumor growth [PMID:23758232, PMID:29976840]. SALL4 additionally couples to DNA methyltransferases [PMID:22128185] and to a panel of chromatin modifiers including MLL, DOT1L, LSD1/KDM1A and HDAC2 to set H3K4me3, H3K79me2/3 and acetylation marks at target promoters in leukemic and other contexts [PMID:24051379, PMID:25737450, PMID:28974232, PMID:34417458]. In germ-cell and progenitor systems SALL4 antagonizes PLZF to balance self-renewal against differentiation [PMID:22385656] and suppresses somatic-program genes [PMID:25263278], and it sustains WNT/β-catenin-driven neuromesodermal progenitors during body elongation [PMID:31235634]. Germline loss models limb and heart malformation consistent with Okihiro/Holt-Oram syndromes through a Tbx5–Sall4 feed-forward circuit [PMID:16380715]. Across cancers SALL4 drives oncogenic transcriptional programs—activating c-Myc, CD44, VEGF and glycolytic genes—and shapes the tumor immune microenvironment, with HBV/STAT3 signaling driving its re-expression in hepatocellular carcinoma [PMID:29593314, PMID:27797380].","teleology":[{"year":2005,"claim":"Established SALL4 as a developmentally regulated patterning gene whose dosage controls limb and heart morphogenesis, anchoring its physiological relevance to human malformation syndromes.","evidence":"Mouse gene-trap genetics with epistasis against Tbx5 and phenotypic analysis","pmids":["16380715"],"confidence":"High","gaps":["Direct SALL4 target genes mediating limb/heart patterning not defined","Molecular nature of the Tbx5–Sall4 feed-forward circuit unresolved"]},{"year":2006,"claim":"Placed SALL4 at the top of the pluripotency network by showing it directly activates Oct4 and physically partners with NANOG in a positive autoregulatory loop, answering how SALL4 enforces stem-cell identity.","evidence":"ChIP, reporter assays, in vivo zygote siRNA, affinity-MS, reciprocal Co-IP and GST pulldown in ES cells","pmids":["16980957","16840789"],"confidence":"High","gaps":["Did not define the DNA motif SALL4 recognizes","Mechanism of transactivation domain not mapped"]},{"year":2006,"claim":"Identified an upstream input by linking canonical Wnt/TCF-LEF signaling to SALL4 promoter activation, beginning to explain how SALL4 expression is set.","evidence":"SALL4 promoter reporter assays with TCF/LEF site mutagenesis and LEF1/TCF4E transfection","pmids":["16899215"],"confidence":"Medium","gaps":["No in vivo ChIP confirmation of TCF/LEF occupancy","Reporter-based, single lab"]},{"year":2007,"claim":"Connected SALL4 to self-renewal effectors and to activating chromatin marks by showing it activates Bmi-1 alongside elevated H3K4me3/H3K79me2, revealing an epigenetic activation mode.","evidence":"Reporter assays, ChIP in myeloid stem cells, siRNA, transgenic and knockout mice","pmids":["17557835"],"confidence":"High","gaps":["Histone methyltransferases responsible not yet identified","Mechanism coupling SALL4 binding to mark deposition unknown"]},{"year":2008,"claim":"Demonstrated cell-autonomous requirement and lineage-specific rewiring, showing SALL4 drives both embryonic and extraembryonic endoderm circuits using distinct target sets.","evidence":"Conditional knockout blastocyst culture, chimera analysis, genome-wide ChIP-chip and siRNA in ESC and XEN cells","pmids":["17060609","18804426"],"confidence":"High","gaps":["How SALL4 selects context-specific targets not explained","Cofactors switching ESC vs XEN programs unidentified"]},{"year":2009,"claim":"Defined SALL4's repressive arm by showing it associates with the HDAC-bearing NuRD complex and co-occupies PTEN/SALL1 promoters, establishing SALL4 as a recruiter of corepressor machinery.","evidence":"Tandem MS of immunocomplexes, Co-IP, HDAC activity assay, ChIP, transgenic mouse","pmids":["19440552"],"confidence":"High","gaps":["Fraction of SALL4 bound to NuRD versus free not quantified","Whether SALL4 recruits NuRD to chromatin not directly tested"]},{"year":2011,"claim":"Extended the repression mechanism to DNA methylation, showing SALL4 binds DNMT1/3A/3B and increases CpG methylation at silenced targets such as PTEN.","evidence":"Co-IP, DNMT enzyme activity assay, ChIP, bisulfite sequencing, VPA/5-azaC inhibitors","pmids":["22128185"],"confidence":"High","gaps":["Direct recruitment of DNMTs to specific loci not resolved at genome scale","Interplay between NuRD and DNMT repression not dissected"]},{"year":2012,"claim":"Revealed a competitive chromatin-partitioning mechanism with PLZF that sets the self-renewal/differentiation switch in spermatogonial progenitors.","evidence":"Co-IP, ChIP, genetic knockout/overexpression and Kit/Sall1 readouts in SPCs","pmids":["22385656"],"confidence":"High","gaps":["Structural basis of mutual chromatin displacement unknown","Generality beyond germline progenitors untested at this stage"]},{"year":2013,"claim":"Validated SALL4–NuRD repression as a druggable oncogenic dependency by showing peptide disruption releases PTEN and inhibits hepatocellular carcinoma tumorigenesis.","evidence":"RNAi loss-of-function, xenografts, N-terminal peptide blockade, expression analysis","pmids":["23758232"],"confidence":"High","gaps":["Peptide pharmacology and delivery not characterized","Whether activator functions persist after disruption not yet shown"]},{"year":2013,"claim":"Built the SALL4/MLL/HOXA9 leukemogenic axis, showing SALL4 binds HOXA9, partners with MLL, and deposits activating marks to drive myeloid leukemia.","evidence":"ChIP, reciprocal Co-IP, siRNA, replating and in vivo AML transplantation","pmids":["24051379"],"confidence":"High","gaps":["Direct enzymatic basis of mark deposition not isolated","Relationship to NuRD repression at the same cells unclear"]},{"year":2013,"claim":"Expanded SALL4's oncogenic activator targets to c-Myc and to adhesion/EMT regulators (CDH1/ZEB1), broadening its pro-tumor transcriptional program.","evidence":"ChIP, gain/loss-of-function, xenograft (c-Myc); shRNA/overexpression with motility assays (CDH1/ZEB1)","pmids":["24336327","23954296"],"confidence":"Medium","gaps":["No direct ChIP at CDH1/ZEB1 promoters","Single-lab target validations"]},{"year":2015,"claim":"Linked SALL4 to histone demethylase recruitment, showing SALL4 binds RARα and recruits LSD1/KDM1A to block ATRA-induced differentiation in AML.","evidence":"Co-IP for RARα and LSD1, ChIP for histone methylation, knockdown, flow cytometry differentiation","pmids":["25737450"],"confidence":"High","gaps":["Direct LSD1 catalytic contribution at SALL4 targets not isolated","Generality across leukemia subtypes untested here"]},{"year":2016,"claim":"Challenged the obligate SALL4–NuRD recruitment model by showing SALL4 is dispensable for ES-cell pluripotency and instead acts as an enhancer-binding restraint on neural genes, with much SALL4 acting independently of NuRD.","evidence":"Conditional ESC knockout, ChIP-seq, quantitative MS of NuRD interaction, RNA-seq, differentiation assays","pmids":["27471257"],"confidence":"High","gaps":["Reconciliation with NuRD-recruitment claims context-dependent and unresolved","How free SALL4 represses transcription mechanistically unclear"]},{"year":2016,"claim":"Established SALL4's roles in germline and maternal epigenetic programming, including oocyte maturation and intron-biased spermatogonial binding distinct from PLZF.","evidence":"Maternal CRISPR knockout with DNA-methylation/histone profiling; spermatogonial ChIP-seq with motif analysis and knockdown","pmids":["28031467","27068105"],"confidence":"High","gaps":["Direct demethylase targets driving oocyte phenotype not pinpointed","Functional meaning of intronic SALL4 binding unresolved"]},{"year":2017,"claim":"Consolidated SALL4 as a chromatin-modifier hub in spermatogonia and leukemia, repressing Foxl1/Dusp4 via NuRD and co-occupying MLL-AF9 targets with DOT1L/LSD1, with leukemia-selective dependency.","evidence":"Inducible knockouts, Co-IP (NuRD, DOT1L, LSD1), ChIP/ChIP-seq, apoptosis/cell-cycle and in vivo transplantation","pmids":["28867346","28974232"],"confidence":"High","gaps":["Which modifier interaction dominates at a given locus unclear","Selectivity for malignant over normal cells mechanistically undefined"]},{"year":2018,"claim":"Resolved the atomic basis of SALL4–NuRD binding and delivered a high-affinity disruptor peptide that reprograms SALL4 to an activator and shrinks tumors, converting the corepressor interface into a therapeutic target.","evidence":"X-ray crystallography of SALL4(1–12)–RBBP4, peptide engineering, transcriptome profiling, xenograft","pmids":["29976840"],"confidence":"High","gaps":["In vivo deliverability/pharmacokinetics of FFW peptide not established","Off-target effects on other RBBP4 partners not assessed"]},{"year":2018,"claim":"Identified SALL4 as a regulator of the tumor immune microenvironment, showing HBV/STAT3-driven SALL4 represses miR-200c to de-repress PD-L1 and promote T-cell exhaustion in HCC.","evidence":"ChIP, miR-200c 3'-UTR reporter, pathway over/knockdown, T-cell exhaustion assays, clinical correlation","pmids":["29593314"],"confidence":"Medium","gaps":["Single-lab axis","In vivo causality of each node not fully separated"]},{"year":2018,"claim":"Connected SALL4 to metastatic and stemness programs in solid tumors through direct activation of TGF-β1 and a KHDRBS3–CD44 splicing axis.","evidence":"ChIP/reporter and TGF-β1 rescue (gastric); shRNA/overexpression with splicing isoform analysis (breast)","pmids":["30349378","29356399"],"confidence":"Medium","gaps":["No direct ChIP at KHDRBS3 promoter","Single-lab, context-specific findings"]},{"year":2019,"claim":"Showed SALL4 sustains WNT/β-catenin-dependent neuromesodermal progenitors to control mesoderm-versus-neural fate during body elongation, integrating its developmental and signaling roles.","evidence":"Conditional TCre knockout, RNA-seq, SALL4 ChIP-seq, WNT reporters, embryonic phenotyping","pmids":["31235634"],"confidence":"High","gaps":["Direct WNT-pathway target of SALL4 not pinpointed","Mechanism of fate-balance control downstream of SALL4 unclear"]},{"year":2020,"claim":"Linked SALL4 to metabolic reprogramming by showing direct activation of glycolytic genes (HK-2) and feedback control of its own expression via the Brg1/miR-296-5p axis.","evidence":"ChIP/reporter with glycolysis assays and HK-2 rescue; Brg1 ChIP at SALL4 promoter with miRNA manipulation","pmids":["32489324","32320856"],"confidence":"Medium","gaps":["Single-lab axes","Direct versus indirect metabolic control not fully separated"]},{"year":2021,"claim":"Pinpointed the AT-rich binding zinc-finger cluster as the essential determinant of SALL4 genome occupancy and developmental function, and revealed a context where SALL4 restrains invasiveness via HDAC2.","evidence":"Genome-wide AT-binding screen, domain-specific mutagenesis with embryonic lethality, ChIP-seq/RNA-seq; melanoma KO with HDAC2 co-binding ChIP and HDAC-inhibitor epistasis","pmids":["33406384","34417458"],"confidence":"High","gaps":["Structural basis of AT recognition not solved","How AT-content sensing selects which genes stay silenced unresolved"]},{"year":2023,"claim":"Defined SALL4 as the indispensable NuRD-recruiting factor for chromatin closing during reprogramming and extended its activator role to angiogenic VEGF genes in cancer.","evidence":"ATAC-seq, Co-IP, N-terminal motif deletion and motif-grafting rescue in iPSC reprogramming; ChIP/EMSA/reporter and HUVEC assays for VEGF","pmids":["37208322","37525212"],"confidence":"High","gaps":["Reconciliation of recruiting-NuRD vs NuRD-independent models across systems incomplete","VEGF axis single-lab"]},{"year":null,"claim":"How SALL4 toggles between NuRD-dependent repression and direct activation at individual loci, and the rules by which AT-rich enhancer binding is translated into context-specific gene programs, remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified model reconciling NuRD-recruiting (37208322) and NuRD-independent (27471257) data","Genome-scale determinants of activation versus repression undefined","No structure of the AT-binding zinc-finger cluster on DNA"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,7,14,24,30,34]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[9,0,34]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,5,26,12]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,9]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[9,26]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,7,14]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[2,4,17,18,26,33]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,13,24,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,6,7,18,27,30]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,24,36]}],"complexes":["Mi-2/NuRD"],"partners":["NANOG","MLL","DOT1L","LSD1/KDM1A","RARA","PLZF","HDAC2","RBBP4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UJQ4","full_name":"Sal-like protein 4","aliases":["Zinc finger protein 797","Zinc finger protein SALL4"],"length_aa":1053,"mass_kda":112.2,"function":"Transcription factor with a key role in the maintenance and self-renewal of embryonic and hematopoietic stem cells","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9UJQ4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SALL4","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SALL4","total_profiled":1310},"omim":[{"mim_id":"618365","title":"ZINC FINGER- AND SCAN DOMAIN-CONTAINING PROTEIN 10; ZSCAN10","url":"https://www.omim.org/entry/618365"},{"mim_id":"616837","title":"HUMAN PLURIPOTENCY-ASSOCIATED TRANSCRIPT 5, NONCODING","url":"https://www.omim.org/entry/616837"},{"mim_id":"616374","title":"BEN DOMAIN-CONTAINING PROTEIN 3; BEND3","url":"https://www.omim.org/entry/616374"},{"mim_id":"607343","title":"SAL-LIKE 4; SALL4","url":"https://www.omim.org/entry/607343"},{"mim_id":"607323","title":"DUANE-RADIAL RAY SYNDROME; DRRS","url":"https://www.omim.org/entry/607323"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"testis","ntpm":3.8},{"tissue":"thyroid gland","ntpm":5.6}],"url":"https://www.proteinatlas.org/search/SALL4"},"hgnc":{"alias_symbol":["dJ1112F19.1","ZNF797"],"prev_symbol":[]},"alphafold":{"accession":"Q9UJQ4","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UJQ4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UJQ4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UJQ4-F1-predicted_aligned_error_v6.png","plddt_mean":51.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SALL4","jax_strain_url":"https://www.jax.org/strain/search?query=SALL4"},"sequence":{"accession":"Q9UJQ4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UJQ4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UJQ4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UJQ4"}},"corpus_meta":[{"pmid":"16980957","id":"PMC_16980957","title":"Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1.","date":"2006","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16980957","citation_count":460,"is_preprint":false},{"pmid":"16840789","id":"PMC_16840789","title":"Sall4 interacts with Nanog and co-occupies Nanog genomic sites in embryonic stem cells.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16840789","citation_count":234,"is_preprint":false},{"pmid":"23758232","id":"PMC_23758232","title":"Oncofetal gene SALL4 in aggressive hepatocellular carcinoma.","date":"2013","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23758232","citation_count":205,"is_preprint":false},{"pmid":"18804426","id":"PMC_18804426","title":"Sall4 regulates distinct transcription circuitries in different blastocyst-derived stem cell lineages.","date":"2008","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/18804426","citation_count":189,"is_preprint":false},{"pmid":"19390421","id":"PMC_19390421","title":"SALL4 is a novel diagnostic marker for testicular germ cell tumors.","date":"2009","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19390421","citation_count":170,"is_preprint":false},{"pmid":"23175232","id":"PMC_23175232","title":"Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers.","date":"2013","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23175232","citation_count":160,"is_preprint":false},{"pmid":"31143524","id":"PMC_31143524","title":"SALL4-mediated upregulation of exosomal miR-146a-5p drives T-cell exhaustion by M2 tumor-associated macrophages in HCC.","date":"2019","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/31143524","citation_count":157,"is_preprint":false},{"pmid":"17060609","id":"PMC_17060609","title":"Murine inner cell mass-derived lineages depend on Sall4 function.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17060609","citation_count":156,"is_preprint":false},{"pmid":"24525512","id":"PMC_24525512","title":"SALL4 expression in germ cell and non-germ cell tumors: a systematic immunohistochemical study of 3215 cases.","date":"2014","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24525512","citation_count":153,"is_preprint":false},{"pmid":"22385656","id":"PMC_22385656","title":"Functional antagonism between Sall4 and Plzf defines germline progenitors.","date":"2012","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/22385656","citation_count":143,"is_preprint":false},{"pmid":"19440552","id":"PMC_19440552","title":"Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19440552","citation_count":143,"is_preprint":false},{"pmid":"16380715","id":"PMC_16380715","title":"Cooperative and antagonistic interactions between Sall4 and Tbx5 pattern the mouse limb and heart.","date":"2005","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16380715","citation_count":137,"is_preprint":false},{"pmid":"17557835","id":"PMC_17557835","title":"Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17557835","citation_count":131,"is_preprint":false},{"pmid":"19476507","id":"PMC_19476507","title":"Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts.","date":"2009","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/19476507","citation_count":126,"is_preprint":false},{"pmid":"18487508","id":"PMC_18487508","title":"SALL4 is a key regulator of survival and apoptosis in human leukemic cells.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18487508","citation_count":125,"is_preprint":false},{"pmid":"25919570","id":"PMC_25919570","title":"MicroRNA-33b Inhibits Breast Cancer Metastasis by Targeting HMGA2, SALL4 and Twist1.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25919570","citation_count":124,"is_preprint":false},{"pmid":"24012616","id":"PMC_24012616","title":"The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma.","date":"2013","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/24012616","citation_count":121,"is_preprint":false},{"pmid":"24276240","id":"PMC_24276240","title":"SALL4, a novel marker for human gastric carcinogenesis and metastasis.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24276240","citation_count":104,"is_preprint":false},{"pmid":"26892498","id":"PMC_26892498","title":"SALL4, the missing link between stem cells, development and cancer.","date":"2016","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/26892498","citation_count":97,"is_preprint":false},{"pmid":"19185577","id":"PMC_19185577","title":"Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells.","date":"2008","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19185577","citation_count":94,"is_preprint":false},{"pmid":"29593314","id":"PMC_29593314","title":"Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29593314","citation_count":90,"is_preprint":false},{"pmid":"23326552","id":"PMC_23326552","title":"SALL4 expression in gonocytes and spermatogonial clones of postnatal mouse testes.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23326552","citation_count":88,"is_preprint":false},{"pmid":"24336327","id":"PMC_24336327","title":"SALL4 is a new target in endometrial cancer.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24336327","citation_count":85,"is_preprint":false},{"pmid":"27068105","id":"PMC_27068105","title":"The regulatory repertoire of PLZF and SALL4 in undifferentiated spermatogonia.","date":"2016","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27068105","citation_count":83,"is_preprint":false},{"pmid":"25444934","id":"PMC_25444934","title":"SALL4: an emerging cancer biomarker and target.","date":"2014","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/25444934","citation_count":80,"is_preprint":false},{"pmid":"30349378","id":"PMC_30349378","title":"SALL4 activates TGF-β/SMAD signaling pathway to induce EMT and promote gastric cancer metastasis.","date":"2018","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/30349378","citation_count":74,"is_preprint":false},{"pmid":"12826753","id":"PMC_12826753","title":"Cloning and expression analysis of SALL4, the murine homologue of the gene mutated in Okihiro syndrome.","date":"2002","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/12826753","citation_count":73,"is_preprint":false},{"pmid":"23363002","id":"PMC_23363002","title":"Role of SALL4 in the progression and metastasis of colorectal cancer.","date":"2013","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/23363002","citation_count":73,"is_preprint":false},{"pmid":"16998462","id":"PMC_16998462","title":"Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia.","date":"2006","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/16998462","citation_count":72,"is_preprint":false},{"pmid":"21725617","id":"PMC_21725617","title":"Overexpression of SALL4 in lung cancer and its importance in cell proliferation.","date":"2011","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21725617","citation_count":71,"is_preprint":false},{"pmid":"16899215","id":"PMC_16899215","title":"SALL4 is directly activated by TCF/LEF in the canonical Wnt signaling pathway.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16899215","citation_count":67,"is_preprint":false},{"pmid":"29416741","id":"PMC_29416741","title":"Long noncoding RNA DANCR is activated by SALL4 and promotes the proliferation and invasion of gastric cancer cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29416741","citation_count":64,"is_preprint":false},{"pmid":"23811124","id":"PMC_23811124","title":"Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4.","date":"2013","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23811124","citation_count":63,"is_preprint":false},{"pmid":"27471257","id":"PMC_27471257","title":"Sall4 controls differentiation of pluripotent cells independently of the Nucleosome Remodelling and Deacetylation (NuRD) complex.","date":"2016","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27471257","citation_count":60,"is_preprint":false},{"pmid":"22128185","id":"PMC_22128185","title":"Stem cell gene SALL4 suppresses transcription through recruitment of DNA methyltransferases.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22128185","citation_count":57,"is_preprint":false},{"pmid":"28867346","id":"PMC_28867346","title":"Germline Stem Cell Activity Is Sustained by SALL4-Dependent Silencing of Distinct Tumor Suppressor Genes.","date":"2017","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28867346","citation_count":56,"is_preprint":false},{"pmid":"18818376","id":"PMC_18818376","title":"Sall1, sall2, and sall4 are required for neural tube closure in mice.","date":"2008","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18818376","citation_count":55,"is_preprint":false},{"pmid":"29976840","id":"PMC_29976840","title":"Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29976840","citation_count":52,"is_preprint":false},{"pmid":"31216469","id":"PMC_31216469","title":"Induction of Pluripotent Stem Cells from Mouse Embryonic Fibroblasts by Jdp2-Jhdm1b-Mkk6-Glis1-Nanog-Essrb-Sall4.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31216469","citation_count":44,"is_preprint":false},{"pmid":"35216168","id":"PMC_35216168","title":"SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35216168","citation_count":42,"is_preprint":false},{"pmid":"21305648","id":"PMC_21305648","title":"Dedifferentiation and the role of sall4 in reprogramming and patterning during amphibian limb regeneration.","date":"2011","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/21305648","citation_count":42,"is_preprint":false},{"pmid":"30423818","id":"PMC_30423818","title":"miR-103/miR-195/miR-15b Regulate SALL4 and Inhibit Proliferation and Migration in Glioma.","date":"2018","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30423818","citation_count":42,"is_preprint":false},{"pmid":"24051379","id":"PMC_24051379","title":"A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24051379","citation_count":41,"is_preprint":false},{"pmid":"28031467","id":"PMC_28031467","title":"Maternal Sall4 Is Indispensable for Epigenetic Maturation of Mouse Oocytes.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28031467","citation_count":40,"is_preprint":false},{"pmid":"25359397","id":"PMC_25359397","title":"The expression of SALL4 in patients with gliomas: high level of SALL4 expression is correlated with poor outcome.","date":"2014","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25359397","citation_count":40,"is_preprint":false},{"pmid":"29356399","id":"PMC_29356399","title":"SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer.","date":"2018","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29356399","citation_count":40,"is_preprint":false},{"pmid":"32489324","id":"PMC_32489324","title":"SALL4 promotes gastric cancer progression via hexokinase II mediated glycolysis.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/32489324","citation_count":39,"is_preprint":false},{"pmid":"28887597","id":"PMC_28887597","title":"SALL4 suppresses PTEN expression to promote glioma cell proliferation via PI3K/AKT signaling pathway.","date":"2017","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28887597","citation_count":38,"is_preprint":false},{"pmid":"23954296","id":"PMC_23954296","title":"Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer.","date":"2013","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/23954296","citation_count":38,"is_preprint":false},{"pmid":"30907073","id":"PMC_30907073","title":"SALL4 induces radioresistance in nasopharyngeal carcinoma via the ATM/Chk2/p53 pathway.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30907073","citation_count":37,"is_preprint":false},{"pmid":"27819668","id":"PMC_27819668","title":"SALL4 promotes gastric cancer progression through activating CD44 expression.","date":"2016","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/27819668","citation_count":37,"is_preprint":false},{"pmid":"29308206","id":"PMC_29308206","title":"SALL4 as a transcriptional and epigenetic regulator in normal and leukemic hematopoiesis.","date":"2018","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/29308206","citation_count":36,"is_preprint":false},{"pmid":"33406384","id":"PMC_33406384","title":"SALL4 controls cell fate in response to DNA base composition.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33406384","citation_count":34,"is_preprint":false},{"pmid":"27705911","id":"PMC_27705911","title":"Targeting SALL4 by entinostat in lung cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27705911","citation_count":33,"is_preprint":false},{"pmid":"32320856","id":"PMC_32320856","title":"miR-296-5p suppresses stem cell potency of hepatocellular carcinoma cells via regulating Brg1/Sall4 axis.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/32320856","citation_count":33,"is_preprint":false},{"pmid":"28759035","id":"PMC_28759035","title":"SALL4 promotes glycolysis and chromatin remodeling via modulating HP1α-Glut1 pathway.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28759035","citation_count":32,"is_preprint":false},{"pmid":"25646965","id":"PMC_25646965","title":"Significance of SALL4 as a drug‑resistant factor in lung cancer.","date":"2015","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25646965","citation_count":31,"is_preprint":false},{"pmid":"28974232","id":"PMC_28974232","title":"The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.","date":"2017","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28974232","citation_count":31,"is_preprint":false},{"pmid":"27797380","id":"PMC_27797380","title":"DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27797380","citation_count":31,"is_preprint":false},{"pmid":"31235634","id":"PMC_31235634","title":"Sall4 regulates neuromesodermal progenitors and their descendants during body elongation in mouse embryos.","date":"2019","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31235634","citation_count":30,"is_preprint":false},{"pmid":"25263278","id":"PMC_25263278","title":"Sall4 is essential for mouse primordial germ cell specification by suppressing somatic cell program genes.","date":"2015","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/25263278","citation_count":30,"is_preprint":false},{"pmid":"37208322","id":"PMC_37208322","title":"The NuRD complex cooperates with SALL4 to orchestrate reprogramming.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37208322","citation_count":29,"is_preprint":false},{"pmid":"19781444","id":"PMC_19781444","title":"Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes.","date":"2009","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19781444","citation_count":28,"is_preprint":false},{"pmid":"24463278","id":"PMC_24463278","title":"Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target.","date":"2014","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24463278","citation_count":28,"is_preprint":false},{"pmid":"36010677","id":"PMC_36010677","title":"SALL4: An Intriguing Therapeutic Target in Cancer Treatment.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36010677","citation_count":27,"is_preprint":false},{"pmid":"32835442","id":"PMC_32835442","title":"SALL4 promotes tumor progression in breast cancer by targeting EMT.","date":"2020","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/32835442","citation_count":27,"is_preprint":false},{"pmid":"22150312","id":"PMC_22150312","title":"The role of stem cell factor SALL4 in leukemogenesis.","date":"2011","source":"Critical reviews in oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22150312","citation_count":27,"is_preprint":false},{"pmid":"26317546","id":"PMC_26317546","title":"SALL4 is a novel therapeutic target in intrahepatic cholangiocarcinoma.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26317546","citation_count":27,"is_preprint":false},{"pmid":"34417458","id":"PMC_34417458","title":"Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34417458","citation_count":26,"is_preprint":false},{"pmid":"26779651","id":"PMC_26779651","title":"Expression and clinical significance of SALL4 and β-catenin in colorectal cancer.","date":"2016","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/26779651","citation_count":25,"is_preprint":false},{"pmid":"27601921","id":"PMC_27601921","title":"Knockdown of Sall4 inhibits intrahepatic cholangiocarcinoma cell migration and invasion in ICC-9810 cells.","date":"2016","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27601921","citation_count":24,"is_preprint":false},{"pmid":"24827994","id":"PMC_24827994","title":"Differential SALL4 immunoexpression in malignant rhabdoid tumours and epithelioid sarcomas.","date":"2014","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/24827994","citation_count":23,"is_preprint":false},{"pmid":"18781635","id":"PMC_18781635","title":"Sall4 isoforms act during proximal-distal and anterior-posterior axis formation in the mouse embryo.","date":"2008","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/18781635","citation_count":23,"is_preprint":false},{"pmid":"32948804","id":"PMC_32948804","title":"An IMiD-induced SALL4 degron system for selective degradation of target proteins.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/32948804","citation_count":23,"is_preprint":false},{"pmid":"26617716","id":"PMC_26617716","title":"Inhibition of SALL4 suppresses carcinogenesis of colorectal cancer via regulating Gli1 expression.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26617716","citation_count":22,"is_preprint":false},{"pmid":"38355684","id":"PMC_38355684","title":"SALL4 promotes cancer stem-like cell phenotype and radioresistance in oral squamous cell carcinomas via methyltransferase-like 3-mediated m6A modification.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38355684","citation_count":21,"is_preprint":false},{"pmid":"33644042","id":"PMC_33644042","title":"Up-Regulation of SALL4 Is Associated With Survival and Progression via Putative WNT Pathway in Gastric Cancer.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33644042","citation_count":21,"is_preprint":false},{"pmid":"31009138","id":"PMC_31009138","title":"miR-188-5p emerges as an oncomiRNA to promote gastric cancer cell proliferation and migration via upregulation of SALL4.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31009138","citation_count":21,"is_preprint":false},{"pmid":"33718351","id":"PMC_33718351","title":"Sall4 and Myocd Empower Direct Cardiac Reprogramming From Adult Cardiac Fibroblasts After Injury.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33718351","citation_count":20,"is_preprint":false},{"pmid":"34732693","id":"PMC_34732693","title":"miR-497-5p/SALL4 axis promotes stemness phenotype of choriocarcinoma and forms a feedback loop with DNMT-mediated epigenetic regulation.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34732693","citation_count":20,"is_preprint":false},{"pmid":"27576349","id":"PMC_27576349","title":"SOX1 is correlated to stemness state regulator SALL4 through progression and invasiveness of esophageal squamous cell carcinoma.","date":"2016","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/27576349","citation_count":20,"is_preprint":false},{"pmid":"32386479","id":"PMC_32386479","title":"Upregulation of SNHG12 accelerates cell proliferation, migration, invasion and restrain cell apoptosis in breast cancer by enhancing regulating SALL4 expression via sponging miR-15a-5p.","date":"2020","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/32386479","citation_count":20,"is_preprint":false},{"pmid":"34593523","id":"PMC_34593523","title":"Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34593523","citation_count":19,"is_preprint":false},{"pmid":"25246269","id":"PMC_25246269","title":"Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner.","date":"2014","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/25246269","citation_count":19,"is_preprint":false},{"pmid":"32513235","id":"PMC_32513235","title":"VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.","date":"2020","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/32513235","citation_count":19,"is_preprint":false},{"pmid":"37525212","id":"PMC_37525212","title":"SALL4 promotes angiogenesis in gastric cancer by regulating VEGF expression and targeting SALL4/VEGF pathway inhibits cancer progression.","date":"2023","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/37525212","citation_count":18,"is_preprint":false},{"pmid":"33308020","id":"PMC_33308020","title":"Effect of SALL4 on the Proliferation, Invasion and Apoptosis of Breast Cancer Cells.","date":"2020","source":"Technology in cancer research & treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33308020","citation_count":17,"is_preprint":false},{"pmid":"28322736","id":"PMC_28322736","title":"sall1 and sall4 repress pou5f3 family expression to allow neural patterning, differentiation, and morphogenesis in Xenopus laevis.","date":"2017","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28322736","citation_count":17,"is_preprint":false},{"pmid":"29958885","id":"PMC_29958885","title":"SALL4 suppresses reactive oxygen species in pancreatic ductal adenocarcinoma phenotype via FoxM1/Prx III axis.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29958885","citation_count":17,"is_preprint":false},{"pmid":"23067006","id":"PMC_23067006","title":"The differential expression pattern of the BMI-1, SALL4 and ABCA3 genes in myeloid leukemia.","date":"2012","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/23067006","citation_count":17,"is_preprint":false},{"pmid":"25174577","id":"PMC_25174577","title":"SALL4: engine of cell stemness.","date":"2014","source":"Current gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25174577","citation_count":16,"is_preprint":false},{"pmid":"22555391","id":"PMC_22555391","title":"Role of SALL4 in hematopoiesis.","date":"2012","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/22555391","citation_count":16,"is_preprint":false},{"pmid":"37337914","id":"PMC_37337914","title":"The new advance of SALL4 in cancer: Function, regulation, and implication.","date":"2023","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/37337914","citation_count":16,"is_preprint":false},{"pmid":"34106411","id":"PMC_34106411","title":"SALL-4 and Beta-Catenin Expression in Sinonasal Teratocarcinosarcoma.","date":"2021","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34106411","citation_count":16,"is_preprint":false},{"pmid":"27444278","id":"PMC_27444278","title":"Functional and clinical significance of SALL4 in breast cancer.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27444278","citation_count":16,"is_preprint":false},{"pmid":"26034695","id":"PMC_26034695","title":"Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma.","date":"2014","source":"SpringerPlus","url":"https://pubmed.ncbi.nlm.nih.gov/26034695","citation_count":16,"is_preprint":false},{"pmid":"31388035","id":"PMC_31388035","title":"The role of ESCO2, SALL4 and TBX5 genes in the susceptibility to thalidomide teratogenesis.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31388035","citation_count":15,"is_preprint":false},{"pmid":"25977939","id":"PMC_25977939","title":"The next new target in leukemia: The embryonic stem cell gene SALL4.","date":"2014","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25977939","citation_count":15,"is_preprint":false},{"pmid":"23447551","id":"PMC_23447551","title":"Expression of sall4 in taste buds of zebrafish.","date":"2013","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/23447551","citation_count":15,"is_preprint":false},{"pmid":"25737450","id":"PMC_25737450","title":"Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25737450","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50238,"output_tokens":10092,"usd":0.151047,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20379,"output_tokens":6680,"usd":0.134447,"stage2_stop_reason":"end_turn"},"total_usd":0.285494,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"SALL4 binds to the highly conserved distal enhancer region of the Pou5f1 (Oct4) gene and transcriptionally activates Pou5f1 expression in vivo and in vitro; siRNA knockdown of Sall4 in mouse zygotes reduced both Sall4 and Oct4 mRNAs and expanded Cdx2 expression into the inner cell mass, establishing SALL4 as a direct transcriptional activator of Oct4.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assay, siRNA microinjection into mouse zygotes, in vitro transcription assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ChIP, reporter assay, in vivo siRNA), replicated across ES cell and embryo contexts\",\n      \"pmids\": [\"16980957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SALL4 physically interacts with NANOG in embryonic stem cells (identified by affinity purification/MS, confirmed by Co-IP and GST pulldown); SALL4 and NANOG co-occupy each other's enhancer regions and many shared genomic loci, forming a positive autoregulatory circuit that maintains ES cell-specific enhancer activity.\",\n      \"method\": \"Affinity purification coupled to LC-MS/MS, co-immunoprecipitation, GST pulldown, chromatin immunoprecipitation (ChIP), RNAi knockdown with luciferase enhancer activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP confirmed by GST pulldown and ChIP, multiple orthogonal methods in single study\",\n      \"pmids\": [\"16840789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SALL4 associates with the Mi-2/NuRD (Nucleosome Remodeling and Deacetylase) complex, identified by tandem mass spectrometry of SALL4 immunocomplexes; this complex carries HDAC activity. SALL4 directly represses PTEN and SALL1 transcription through co-occupancy of their promoters with NuRD components, as confirmed by ChIP.\",\n      \"method\": \"Tandem mass spectrometry of SALL4 immunocomplexes, co-immunoprecipitation, HDAC activity assay, ChIP, qRT-PCR, SALL4 transgenic mouse model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — MS-identified complex confirmed by Co-IP and HDAC activity assay, ChIP validation of target gene occupancy, in vivo transgenic confirmation\",\n      \"pmids\": [\"19440552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SALL4 directly binds the Bmi-1 promoter and transcriptionally activates Bmi-1 expression in a dose-dependent manner; SALL4-bound Bmi-1 promoter regions show elevated H3-K4 trimethylation and H3-K79 dimethylation, providing an epigenetic mechanism for SALL4-mediated Bmi-1 upregulation.\",\n      \"method\": \"Luciferase reporter assay with promoter deletion constructs, ChIP from myeloid stem cells, siRNA knockdown in HL-60 cells, SALL4 transgenic mice, gene targeting (heterozygous deletion)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, reporter assay, genetic deletion, and transgenic mouse model all converge on same conclusion\",\n      \"pmids\": [\"17557835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SALL4 represses gene expression through direct interaction with DNA methyltransferases (DNMT1, DNMT3A, DNMT3B); co-IP and DNMT enzyme activity assays confirmed physical interaction; SALL4 isoforms co-occupy their own promoter with DNMTs, and SALL4 overexpression increases CpG island methylation of silenced target genes (including PTEN). HDAC inhibition and DNA methylation inhibition synergistically block SALL4-mediated repression.\",\n      \"method\": \"Co-immunoprecipitation, DNMT enzymatic activity assay, ChIP, luciferase reporter assay, bisulfite sequencing/CpG methylation analysis, pharmacological inhibitors (VPA, 5-azaC)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — biochemical Co-IP + enzyme activity assay + ChIP + methylation analysis, multiple cell types tested\",\n      \"pmids\": [\"22128185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Blocking SALL4–NuRD corepressor interactions (using a peptide targeting SALL4's N-terminal region) releases repression of PTEN and inhibits tumor formation in xenograft models; SALL4 loss-of-function studies confirmed its critical role in hepatocellular carcinoma cell survival and tumorigenicity.\",\n      \"method\": \"Loss-of-function (RNAi), in vivo xenograft assays, peptide inhibitor blocking SALL4–NuRD interaction, gene expression analysis\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic rescue experiment (peptide disruption of SALL4-NuRD) with in vivo xenograft validation, replicated by structural study (PMID 29976840)\",\n      \"pmids\": [\"23758232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structure of SALL4 N-terminal peptide (residues 1–12) complexed with RBBp4 (NuRD chaperone subunit) resolved at 2.7 Å; a therapeutic peptide (FFW) designed from this structure disrupts the SALL4–NuRD interaction with 23 nM affinity, converting SALL4 from a dual repressor-activator to a singular activator mode and inhibiting xenograft tumor growth by 85%.\",\n      \"method\": \"X-ray crystallography, peptide design with systematic truncation/substitution, transcriptome profiling, in vivo xenograft tumor model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional validation by in vivo xenograft and transcriptome profiling\",\n      \"pmids\": [\"29976840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SALL4 directly binds to the HOXA9 promoter in leukemic cells; SALL4 overexpression increases activating histone marks (H3-K4me3, H3-K79me2) at the HOXA9 promoter; SALL4 physically interacts with MLL and co-occupies the HOXA9 promoter with MLL, defining a SALL4/MLL/HOXA9 pathway in myeloid leukemogenesis.\",\n      \"method\": \"ChIP, co-immunoprecipitation (SALL4–MLL interaction), siRNA knockdown, in vitro replating assay, in vivo AML transplantation model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP for SALL4-MLL, ChIP for co-occupancy, both in vitro and in vivo functional validation\",\n      \"pmids\": [\"24051379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SALL4 is dispensable for mouse ES cell pluripotency maintenance; instead, SALL4 functions as an enhancer-binding protein that prevents precocious activation of the neural gene expression program. Although a proportion of SALL4 protein physically associates with NuRD, SALL4 neither recruits NuRD to chromatin nor regulates transcription via NuRD; free SALL4 protein regulates transcription independently of NuRD.\",\n      \"method\": \"Conditional Sall4 knockout in ES cells, genome-wide enhancer binding (ChIP-seq), quantitative proteomics (MS) of NuRD interaction, transcriptome analysis (RNA-seq), differentiation assays\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP-seq, quantitative MS, and KO with transcriptome, single lab but multiple orthogonal methods; contradicts some NuRD-recruitment claims (PMID 19440552)\",\n      \"pmids\": [\"27471257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SALL4 binds AT-rich genomic motifs via a specific zinc-finger cluster; mutation of this AT-binding domain drastically reduces SALL4 genome occupancy and prematurely upregulates genes in proportion to their AT content, causing precocious neural differentiation. This AT-binding zinc-finger cluster is functionally essential, as its inactivation mimics full Sall4 null phenotypes including embryonic lethality; deletion of two other zinc-finger clusters was phenotypically neutral.\",\n      \"method\": \"Genome-wide screen for AT-binding proteins, domain-specific mutagenesis, ChIP-seq, RNA-seq, mouse knockout (domain-specific), embryonic lethality assessment\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vivo mutagenesis with embryonic lethality, ChIP-seq and transcriptome, multiple orthogonal methods revealing precise mechanistic domain\",\n      \"pmids\": [\"33406384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SALL4 is directly activated by TCF/LEF transcription factors in the canonical Wnt signaling pathway; a consensus TCF/LEF-binding site within a 31 bp minimal SALL4 promoter region is required, as mutation of this site reduces promoter activation by LEF1 and TCF4E.\",\n      \"method\": \"SALL4 promoter cloning, luciferase reporter assay, site-directed mutagenesis of TCF/LEF binding site, transient transfection with LEF1 and TCF4E\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — reporter assay with mutagenesis in single lab, no in vivo ChIP confirmation of TCF/LEF occupancy\",\n      \"pmids\": [\"16899215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Tbx5 regulates Sall4 expression in developing mouse forelimb and heart; Tbx5 and Sall4 interact both positively and negatively in a feed-forward circuit to regulate anterior forelimb and heart patterning; Sall4 heterozygous gene-trap mice exhibit limb and heart defects modeling human Okihiro/Holt-Oram syndromes.\",\n      \"method\": \"Mouse genetics (Sall4 gene-trap heterozygous), in situ hybridization, compound mutant analysis (epistasis), expression analysis in Tbx5 mutants\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with multiple mutant combinations, in vivo phenotypic analysis, expression downstream relationship established\",\n      \"pmids\": [\"16380715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In differentiating spermatogonial progenitor cells (SPCs), SALL4 physically interacts with PLZF; SALL4 sequesters PLZF to non-cognate chromatin domains to derepress Kit expression (a PLZF-repressed differentiation target); conversely, PLZF displaces SALL4 from cognate chromatin to induce Sall1 expression, creating a mutual antagonism that defines the self-renewal vs. differentiation balance.\",\n      \"method\": \"Co-immunoprecipitation (SALL4-PLZF interaction), ChIP, genetic knockout/overexpression in SPCs, Kit expression analysis\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP confirmed interaction, ChIP established chromatin displacement mechanism, genetic models validated functional outcome\",\n      \"pmids\": [\"22385656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Sall4 is cell-autonomously required for development of epiblast and primitive endoderm from the inner cell mass; Sall4-deficient blastocysts cannot give rise to embryonic or extraembryonic endoderm stem cell lines. Trophoblast lineage development is unaffected by Sall4 loss.\",\n      \"method\": \"Conditional mouse knockout (Sall4-null), blastocyst culture and stem cell line derivation, chimera analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic null mouse with cell-autonomous rescue experiment and lineage-specific phenotype\",\n      \"pmids\": [\"17060609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Sall4 regulates distinct gene sets and transcriptional circuits in embryonic stem cells (ESCs) versus extraembryonic endoderm (XEN) cells; in ESCs, Sall4 forms an interconnected autoregulatory network with Oct4, Sox2, and Nanog; in XEN cells, Sall4 regulates Gata4, Gata6, Sox7, and Sox17. Depletion of Sall4 in XEN cells disrupts self-renewal and induces differentiation.\",\n      \"method\": \"Genome-wide ChIP-chip, siRNA knockdown in both ESC and XEN cells, gene expression profiling, differentiation assays\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP in two cell types, functional KD with differentiation phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"18804426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Maternal SALL4 is required for epigenetic maturation of mouse oocytes; maternal-specific Sall4 deletion (via CRISPR/Cas9) causes oocyte developmental arrest at the germinal vesicle stage with non-surrounded nucleus and prevents meiosis resumption. Loss of maternal Sall4 causes failure of DNA methylation establishment and dysregulation of H3K4me3 and H3K27me3 modifications by altering expression of histone demethylases Kdm5b, Kdm6a, and Kdm6b.\",\n      \"method\": \"Maternal-specific CRISPR/Cas9 knockout, bisulfite sequencing (DNA methylation), ChIP for histone marks, gene expression analysis (qRT-PCR)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with mechanistic histone and DNA methylation profiling, multiple orthogonal methods\",\n      \"pmids\": [\"28031467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SALL4 associates with the NuRD co-repressor complex in undifferentiated spermatogonia and represses tumor suppressor genes Foxl1 and Dusp4; aberrant Foxl1 activation inhibits undifferentiated cell growth and survival, while DUSP4 suppresses self-renewal pathways. Inducible knockout showed short-term integrity of differentiating spermatogonia requires SALL4, while long-term undifferentiated spermatogonial function and stem cell-driven regeneration also depend on SALL4.\",\n      \"method\": \"Inducible knockout mouse model, Co-IP (SALL4-NuRD), ChIP, gene expression analysis, functional regeneration assays\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible KO with NuRD Co-IP and ChIP validation of target gene repression, in vivo regeneration assay\",\n      \"pmids\": [\"28867346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SALL4 directly associates with retinoic acid receptor α (RARα) and modulates ATRA target gene expression; SALL4 recruits lysine-specific histone demethylase 1 (LSD1/KDM1A) to target genes and alters their histone methylation status, thereby blocking ATRA-induced AML differentiation. Co-inhibition of LSD1 and SALL4 with ATRA produced the strongest anti-AML effect.\",\n      \"method\": \"Co-immunoprecipitation (SALL4-RARα and SALL4-LSD1), ChIP for histone methylation, siRNA knockdown, SALL4 overexpression, flow cytometry differentiation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP for two distinct interaction partners (RARα and LSD1), ChIP for histone marks, functional differentiation assays\",\n      \"pmids\": [\"25737450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In MLL-AF9 leukemia, SALL4 physically interacts with DOT1L (H3K79 methyltransferase) and LSD1/KDM1A, co-occupies MLL-AF9 target gene promoters, and regulates H3K79me2/3 and H3K4me3 marks at those promoters. SALL4 loss in MLL-AF9-transformed cells induced apoptosis and G1 cell cycle arrest; normal hematopoiesis is unaffected by Sall4 deletion.\",\n      \"method\": \"ChIP-seq, Co-immunoprecipitation (SALL4-DOT1L, SALL4-LSD1), mRNA microarray, inducible Cre knockout, apoptosis/cell cycle assays, in vivo leukemia transplantation\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq, Co-IP for two chromatin modifiers, inducible in vivo KO with both in vitro and in vivo phenotyping\",\n      \"pmids\": [\"28974232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SALL4 promotes open chromatin by recruiting ubiquitin E3 ligase CUL4B to HP1α, thereby destabilizing HP1α (heterochromatin protein 1α). This mechanism upregulates Glut1 expression and promotes glycolysis; impaired DNA damage response (DDR) in SALL4-deficient cells can be rescued by restoring Glut1 expression, linking SALL4-HP1α-Glut1 axis to DDR and chemoresistance.\",\n      \"method\": \"Co-immunoprecipitation (SALL4-CUL4B-HP1α), chromatin accessibility assay, glucose uptake/glycolysis assays, rescue experiments with Glut1\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP identifies ternary complex, functional rescue experiments, but single lab with limited orthogonal validation\",\n      \"pmids\": [\"28759035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SALL4 binds to the promoter of miR-146a-5p and directly controls its expression in HCC exosomes; the SALL4/miR-146a-5p regulatory axis drives M2 macrophage polarization and T cell exhaustion (via induction of PD-1 and CTLA-4 on T cells). Blocking this axis reduced inhibitory receptor expression on T cells and delayed HCC progression in a mouse model.\",\n      \"method\": \"ChIP (SALL4 binding to miR-146a-5p promoter), exosome isolation and miRNA quantification, macrophage polarization assays, T cell functional assays, in vivo DEN/CCL4-induced HCC mouse model\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP confirms direct binding at miR-146a-5p promoter, functional in vivo validation, single lab\",\n      \"pmids\": [\"31143524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HBV-induced STAT3 activation drives re-expression of SALL4 in adult hepatocytes; SALL4 then occupies the miR-200c promoter to suppress miR-200c transcription, which in turn de-represses PD-L1 (CD274), promoting T cell exhaustion. The HBV-pSTAT3-SALL4-miR-200c-PD-L1 axis was confirmed by ChIP and miR-200c 3'-UTR reporter assays.\",\n      \"method\": \"ChIP (SALL4 binding to miR-200c promoter), luciferase 3'-UTR reporter assay, overexpression/knockdown of pathway components, T cell exhaustion assays, clinical HCC specimen correlation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and reporter assays establish direct promoter binding, functional T cell assays, single lab\",\n      \"pmids\": [\"29593314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DNA demethylation of CpG sites downstream of the SALL4 transcriptional start site enables binding of OCT4 and STAT3 at those sites, recruitment of chromatin remodeling complex BRG1/BAF, and enhanced RNA polymerase II elongation through the SALL4 locus, thereby driving SALL4 re-expression in HBV-related HCC. BRG1 knockdown reduced SALL4 expression, while BRG1 overexpression increased it.\",\n      \"method\": \"Bisulfite sequencing PCR, ChIP (RNA Pol II, OCT4, STAT3, BRG1 occupancy), sequential ChIP (co-occupancy), BRG1 knockdown/overexpression\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple ChIP assays including sequential ChIP for co-occupancy, functional BRG1 manipulation, single lab\",\n      \"pmids\": [\"27797380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Sall4 is required for mouse primordial germ cell (PGC) specification; conditional inactivation of Sall4 during PGC specification caused somatic program gene derepression (Hoxa1, Hoxb1) in PGC progenitors without impairing stem cell program activation. Sall4 was shown to bind somatic cell program gene loci (occupied by Prdm1 in embryonic carcinoma cells), and since Sall4 and Prdm1 associate with the HDAC repressor complex, Sall4 likely suppresses the somatic program by recruiting this repressor complex with Prdm1.\",\n      \"method\": \"Conditional Sall4 knockout, qRT-PCR for somatic program genes, ChIP (Sall4 binding at Hoxa1/Hoxb1 loci in differentiated ESCs), apoptosis assays\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — conditional KO with ChIP validation in ESC system, in vivo PGC counting; mechanistic link to Prdm1/HDAC is inferred from ChIP context, single lab\",\n      \"pmids\": [\"25263278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Sall4 promotes WNT/β-catenin signaling to maintain neuromesodermal progenitors (NMPs) and control their differentiation balance toward mesodermal versus neural fates during mouse body elongation; SALL4 ChIP-seq identified direct target genes in both mesodermal and neural compartments; Sall4 deletion caused body/tail truncation due to NMP depletion at the trunk-to-tail transition.\",\n      \"method\": \"Conditional Sall4 knockout (TCre), RNA-seq, SALL4 ChIP-seq, WNT/β-catenin signaling reporters, histological and molecular phenotype analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq combined with RNA-seq and conditional KO, multiple orthogonal methods, in vivo embryonic analysis\",\n      \"pmids\": [\"31235634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In undifferentiated spermatogonia, SALL4 preferentially binds gene introns (while PLZF binds gene promoters); SALL4-bound sites contain motifs for the differentiation factor DMRT1. PLZF/SALL4 shared sites predominantly contain only PLZF motifs, indicating non-autonomous binding. Both PLZF- and SALL4-unique target genes involved in SSC self-renewal and differentiation are suppressed following their respective knockdown.\",\n      \"method\": \"ChIP-seq in THY1+ spermatogonia, motif analysis, siRNA knockdown followed by mRNA expression profiling\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq with motif analysis and functional KD in primary cells, single lab but comprehensive approach\",\n      \"pmids\": [\"27068105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"During somatic cell reprogramming, the NuRD complex participates in closing open chromatin in an early phase; SALL4 (but not Jdp2, Glis1, or Esrrb) is indispensable for recruiting endogenous NuRD components. Mutation or deletion of SALL4's N-terminal NuRD-interacting motif abolishes reprogramming efficiency; grafting this motif onto Jdp2 partially rescues reprogramming, establishing the SALL4–NuRD axis as critical for chromatin closing during cell fate transition.\",\n      \"method\": \"ATAC-seq (chromatin accessibility), Co-IP (SALL4-NuRD), domain deletion/mutation, motif grafting rescue experiment, iPSC reprogramming efficiency assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ATAC-seq mechanistic chromatin data, domain-swap rescue experiment, Co-IP, multiple orthogonal methods\",\n      \"pmids\": [\"37208322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SALL4 promotes gastric cancer metastasis by directly binding to the TGF-β1 gene promoter and activating its transcription, thereby activating TGF-β/SMAD signaling and inducing EMT; TGF-β1 knockdown reversed SALL4-mediated promotion of cancer cell motility.\",\n      \"method\": \"ChIP assay (SALL4 binding at TGF-β1 promoter), luciferase reporter assay, microarray, siRNA knockdown, in vivo peritoneal metastasis model\",\n      \"journal\": \"Cancer management and research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and luciferase confirm direct promoter binding; rescue experiment with TGF-β1 KD validates epistasis; single lab\",\n      \"pmids\": [\"30349378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SALL4 binds the CD44 promoter region and transcriptionally activates CD44 expression; CD44 overexpression rescued SALL4 knockdown-mediated inhibition of gastric cancer cell proliferation, migration, and invasion in vitro and in vivo, establishing CD44 as a functional downstream effector of SALL4.\",\n      \"method\": \"ChIP, luciferase reporter assay, shRNA knockdown with tetracycline-inducible system, CD44 rescue experiment, in vivo xenograft model\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and reporter confirm direct binding; epistasis rescue validates mechanism; single lab\",\n      \"pmids\": [\"27819668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SALL4 directly binds the HK-2 (hexokinase II) gene promoter and activates its transcription; HK-2 knockdown abrogated SALL4-promoted glycolysis and reversed SALL4-driven gastric cancer cell proliferation, migration, and invasion, establishing HK-2 as a downstream effector of SALL4-mediated Warburg effect.\",\n      \"method\": \"ChIP, luciferase reporter assay, microarray, glycolysis assays (glucose uptake, lactate, ATP, hexokinase activity), HK-2 rescue experiment, in vivo xenograft and peritoneal metastasis models\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and reporter confirm direct SALL4 binding at HK-2 promoter; epistasis rescue with multiple functional readouts; single lab\",\n      \"pmids\": [\"32489324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SALL4 directly binds the c-Myc promoter region in endometrial cancer cells; SALL4 knockdown decreases c-Myc expression at both mRNA and protein levels, and SALL4 overexpression increases c-Myc, establishing c-Myc as a direct transcriptional target of SALL4 in endometrial tumorigenesis.\",\n      \"method\": \"ChIP, siRNA knockdown, SALL4 overexpression, qRT-PCR, Western blot, in vivo xenograft and metastasis models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP confirms direct promoter binding; gain/loss-of-function validates target regulation; single lab\",\n      \"pmids\": [\"24336327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SALL4 suppresses CDH1 (E-cadherin) expression and positively regulates the CDH1 suppressor ZEB1 in basal-like breast cancer; SALL4 maintains cell dispersion by suppressing intercellular adhesion and cell motility after cell-cell interaction.\",\n      \"method\": \"shRNA knockdown, SALL4 overexpression, cell behavior analysis (adhesion, motility, dispersion assays), gene expression analysis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional KD/OE with phenotypic readout, no direct ChIP for CDH1/ZEB1 promoters; single lab\",\n      \"pmids\": [\"23954296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SALL4 upregulates KHDRBS3 (a splicing factor), which in turn modulates CD44 alternative splicing to produce a specific CD44 variant (CD44v lacking exons 8 and 9) that promotes cancer stemness and anoikis resistance in basal-like breast cancer.\",\n      \"method\": \"shRNA knockdown, gene overexpression, sphere formation assay, CD44 splicing isoform cloning and analysis, anoikis resistance assay\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional epistasis via KD/rescue, splicing isoform cloning validates mechanism, single lab, no direct ChIP at KHDRBS3 promoter\",\n      \"pmids\": [\"29356399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SALL4 negatively regulates melanoma invasiveness through interaction with HDAC2 and direct co-binding to a set of invasiveness gene loci; SALL4 loss or HDAC inhibition promotes an invasive gene expression signature while inhibition of histone acetylation partially reverts SALL4 loss-induced invasiveness.\",\n      \"method\": \"ChIP (SALL4 and HDAC2 co-binding), transcriptional profiling, SALL4 knockout in melanoma mouse model, HDAC inhibitor treatment, in vitro invasion assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP for co-binding, genetic KO in melanoma mouse model, pharmacological epistasis with HDAC inhibitor, multiple orthogonal methods\",\n      \"pmids\": [\"34417458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SALL4 directly binds the promoters of VEGF-A, VEGF-B, and VEGF-C genes and activates their transcription, associated with increased H3K79 and H3K4 histone modifications; SALL4-regulated VEGF expression promotes gastric cancer angiogenesis by recruiting endothelial cells.\",\n      \"method\": \"ChIP, EMSA (electrophoretic mobility shift assay), luciferase reporter assay, SALL4 knockdown/knockout/overexpression, HUVEC functional assays (proliferation, migration, tube formation), in vivo xenograft\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and EMSA confirm direct DNA binding at VEGF promoters, functional endothelial cell assays validate downstream effect; single lab\",\n      \"pmids\": [\"37525212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In Xenopus, sall4 (ortholog of mammalian SALL4) represses pou5f3 family gene expression (orthologs of Oct4/Pou5f1) in the neural plate; sall4 knockdown causes aberrant pou5f3 upregulation and defects in neural patterning, morphogenesis, and differentiation that phenocopy overexpression of pou5f3 genes.\",\n      \"method\": \"Morpholino knockdown of sall1/sall4, in situ hybridization, pou5f3 overexpression rescue/phenocopy experiments in Xenopus\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic epistasis via morpholino KD and pou5f3 overexpression phenocopy; Xenopus ortholog study, single lab\",\n      \"pmids\": [\"28322736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Brg1 (BRG1/SMARCA4) directly binds the SALL4 promoter and enhances SALL4 transcription in HCC cells; miR-296-5p targets Brg1, thereby suppressing SALL4 expression and inhibiting HCC cancer stem cell stemness.\",\n      \"method\": \"ChIP (Brg1 binding to SALL4 promoter), luciferase reporter assay, miR-296-5p overexpression/knockdown, sphere formation assay, in vivo tumorigenesis in NOD/SCID mice\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP confirms Brg1 at SALL4 promoter; functional miRNA/Brg1/SALL4 axis validated; single lab\",\n      \"pmids\": [\"32320856\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SALL4 is a zinc-finger transcription factor that maintains pluripotency and stem cell identity by binding AT-rich genomic enhancers (via a critical AT-binding zinc-finger cluster), directly activating key pluripotency genes (Oct4/Pou5f1, Nanog, Bmi-1, HoxA9, CD44, VEGF, c-Myc) and repressing tumor suppressors (PTEN, SALL1, Foxl1, Dusp4) through physical association with epigenetic co-repressor complexes including Mi-2/NuRD (via its N-terminal motif) and DNA methyltransferases; SALL4 also interacts with NANOG, PLZF, MLL, DOT1L, LSD1/KDM1A, RARα, CUL4B, and HDAC2 to modulate chromatin state at target loci, while its own expression is regulated upstream by TCF/LEF (Wnt signaling), BRG1-mediated chromatin remodeling at demethylated CpG sites, and STAT3 activation downstream of HBV infection.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SALL4 is a zinc-finger transcription factor that governs stem-cell identity and cell-fate transitions by binding AT-rich genomic enhancers through a specific zinc-finger cluster whose inactivation phenocopies the full Sall4-null state, including embryonic lethality and precocious neural differentiation [#9]. In embryonic and extraembryonic stem cells SALL4 operates within an interconnected autoregulatory transcriptional network—physically associating with NANOG and co-occupying shared enhancers [#1], directly activating Oct4/Pou5f1 [#0], and engaging distinct circuits (Oct4/Sox2/Nanog versus Gata4/6/Sox7/17) depending on lineage context [#14]—and is cell-autonomously required for epiblast and primitive endoderm formation from the inner cell mass [#13]. SALL4 functions both as a transcriptional activator and as a repressor: its N-terminal motif recruits the Mi-2/NuRD nucleosome-remodeling and deacetylase complex to close chromatin and silence tumor-suppressor loci such as PTEN and SALL1 [#2, #26], and disruption of this SALL4–NuRD interface by a structurally-defined peptide releases PTEN repression, converts SALL4 to a singular activator, and blocks tumor growth [#5, #6]. SALL4 additionally couples to DNA methyltransferases [#4] and to a panel of chromatin modifiers including MLL, DOT1L, LSD1/KDM1A and HDAC2 to set H3K4me3, H3K79me2/3 and acetylation marks at target promoters in leukemic and other contexts [#7, #17, #18, #33]. In germ-cell and progenitor systems SALL4 antagonizes PLZF to balance self-renewal against differentiation [#12] and suppresses somatic-program genes [#23], and it sustains WNT/β-catenin-driven neuromesodermal progenitors during body elongation [#24]. Germline loss models limb and heart malformation consistent with Okihiro/Holt-Oram syndromes through a Tbx5–Sall4 feed-forward circuit [#11]. Across cancers SALL4 drives oncogenic transcriptional programs—activating c-Myc, CD44, VEGF and glycolytic genes—and shapes the tumor immune microenvironment, with HBV/STAT3 signaling driving its re-expression in hepatocellular carcinoma [#21, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established SALL4 as a developmentally regulated patterning gene whose dosage controls limb and heart morphogenesis, anchoring its physiological relevance to human malformation syndromes.\",\n      \"evidence\": \"Mouse gene-trap genetics with epistasis against Tbx5 and phenotypic analysis\",\n      \"pmids\": [\"16380715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct SALL4 target genes mediating limb/heart patterning not defined\", \"Molecular nature of the Tbx5–Sall4 feed-forward circuit unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed SALL4 at the top of the pluripotency network by showing it directly activates Oct4 and physically partners with NANOG in a positive autoregulatory loop, answering how SALL4 enforces stem-cell identity.\",\n      \"evidence\": \"ChIP, reporter assays, in vivo zygote siRNA, affinity-MS, reciprocal Co-IP and GST pulldown in ES cells\",\n      \"pmids\": [\"16980957\", \"16840789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the DNA motif SALL4 recognizes\", \"Mechanism of transactivation domain not mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified an upstream input by linking canonical Wnt/TCF-LEF signaling to SALL4 promoter activation, beginning to explain how SALL4 expression is set.\",\n      \"evidence\": \"SALL4 promoter reporter assays with TCF/LEF site mutagenesis and LEF1/TCF4E transfection\",\n      \"pmids\": [\"16899215\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo ChIP confirmation of TCF/LEF occupancy\", \"Reporter-based, single lab\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected SALL4 to self-renewal effectors and to activating chromatin marks by showing it activates Bmi-1 alongside elevated H3K4me3/H3K79me2, revealing an epigenetic activation mode.\",\n      \"evidence\": \"Reporter assays, ChIP in myeloid stem cells, siRNA, transgenic and knockout mice\",\n      \"pmids\": [\"17557835\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Histone methyltransferases responsible not yet identified\", \"Mechanism coupling SALL4 binding to mark deposition unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated cell-autonomous requirement and lineage-specific rewiring, showing SALL4 drives both embryonic and extraembryonic endoderm circuits using distinct target sets.\",\n      \"evidence\": \"Conditional knockout blastocyst culture, chimera analysis, genome-wide ChIP-chip and siRNA in ESC and XEN cells\",\n      \"pmids\": [\"17060609\", \"18804426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SALL4 selects context-specific targets not explained\", \"Cofactors switching ESC vs XEN programs unidentified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined SALL4's repressive arm by showing it associates with the HDAC-bearing NuRD complex and co-occupies PTEN/SALL1 promoters, establishing SALL4 as a recruiter of corepressor machinery.\",\n      \"evidence\": \"Tandem MS of immunocomplexes, Co-IP, HDAC activity assay, ChIP, transgenic mouse\",\n      \"pmids\": [\"19440552\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fraction of SALL4 bound to NuRD versus free not quantified\", \"Whether SALL4 recruits NuRD to chromatin not directly tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Extended the repression mechanism to DNA methylation, showing SALL4 binds DNMT1/3A/3B and increases CpG methylation at silenced targets such as PTEN.\",\n      \"evidence\": \"Co-IP, DNMT enzyme activity assay, ChIP, bisulfite sequencing, VPA/5-azaC inhibitors\",\n      \"pmids\": [\"22128185\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct recruitment of DNMTs to specific loci not resolved at genome scale\", \"Interplay between NuRD and DNMT repression not dissected\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed a competitive chromatin-partitioning mechanism with PLZF that sets the self-renewal/differentiation switch in spermatogonial progenitors.\",\n      \"evidence\": \"Co-IP, ChIP, genetic knockout/overexpression and Kit/Sall1 readouts in SPCs\",\n      \"pmids\": [\"22385656\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of mutual chromatin displacement unknown\", \"Generality beyond germline progenitors untested at this stage\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Validated SALL4–NuRD repression as a druggable oncogenic dependency by showing peptide disruption releases PTEN and inhibits hepatocellular carcinoma tumorigenesis.\",\n      \"evidence\": \"RNAi loss-of-function, xenografts, N-terminal peptide blockade, expression analysis\",\n      \"pmids\": [\"23758232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Peptide pharmacology and delivery not characterized\", \"Whether activator functions persist after disruption not yet shown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Built the SALL4/MLL/HOXA9 leukemogenic axis, showing SALL4 binds HOXA9, partners with MLL, and deposits activating marks to drive myeloid leukemia.\",\n      \"evidence\": \"ChIP, reciprocal Co-IP, siRNA, replating and in vivo AML transplantation\",\n      \"pmids\": [\"24051379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct enzymatic basis of mark deposition not isolated\", \"Relationship to NuRD repression at the same cells unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Expanded SALL4's oncogenic activator targets to c-Myc and to adhesion/EMT regulators (CDH1/ZEB1), broadening its pro-tumor transcriptional program.\",\n      \"evidence\": \"ChIP, gain/loss-of-function, xenograft (c-Myc); shRNA/overexpression with motility assays (CDH1/ZEB1)\",\n      \"pmids\": [\"24336327\", \"23954296\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct ChIP at CDH1/ZEB1 promoters\", \"Single-lab target validations\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked SALL4 to histone demethylase recruitment, showing SALL4 binds RARα and recruits LSD1/KDM1A to block ATRA-induced differentiation in AML.\",\n      \"evidence\": \"Co-IP for RARα and LSD1, ChIP for histone methylation, knockdown, flow cytometry differentiation\",\n      \"pmids\": [\"25737450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct LSD1 catalytic contribution at SALL4 targets not isolated\", \"Generality across leukemia subtypes untested here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Challenged the obligate SALL4–NuRD recruitment model by showing SALL4 is dispensable for ES-cell pluripotency and instead acts as an enhancer-binding restraint on neural genes, with much SALL4 acting independently of NuRD.\",\n      \"evidence\": \"Conditional ESC knockout, ChIP-seq, quantitative MS of NuRD interaction, RNA-seq, differentiation assays\",\n      \"pmids\": [\"27471257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with NuRD-recruitment claims context-dependent and unresolved\", \"How free SALL4 represses transcription mechanistically unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established SALL4's roles in germline and maternal epigenetic programming, including oocyte maturation and intron-biased spermatogonial binding distinct from PLZF.\",\n      \"evidence\": \"Maternal CRISPR knockout with DNA-methylation/histone profiling; spermatogonial ChIP-seq with motif analysis and knockdown\",\n      \"pmids\": [\"28031467\", \"27068105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct demethylase targets driving oocyte phenotype not pinpointed\", \"Functional meaning of intronic SALL4 binding unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Consolidated SALL4 as a chromatin-modifier hub in spermatogonia and leukemia, repressing Foxl1/Dusp4 via NuRD and co-occupying MLL-AF9 targets with DOT1L/LSD1, with leukemia-selective dependency.\",\n      \"evidence\": \"Inducible knockouts, Co-IP (NuRD, DOT1L, LSD1), ChIP/ChIP-seq, apoptosis/cell-cycle and in vivo transplantation\",\n      \"pmids\": [\"28867346\", \"28974232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which modifier interaction dominates at a given locus unclear\", \"Selectivity for malignant over normal cells mechanistically undefined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved the atomic basis of SALL4–NuRD binding and delivered a high-affinity disruptor peptide that reprograms SALL4 to an activator and shrinks tumors, converting the corepressor interface into a therapeutic target.\",\n      \"evidence\": \"X-ray crystallography of SALL4(1–12)–RBBP4, peptide engineering, transcriptome profiling, xenograft\",\n      \"pmids\": [\"29976840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo deliverability/pharmacokinetics of FFW peptide not established\", \"Off-target effects on other RBBP4 partners not assessed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified SALL4 as a regulator of the tumor immune microenvironment, showing HBV/STAT3-driven SALL4 represses miR-200c to de-repress PD-L1 and promote T-cell exhaustion in HCC.\",\n      \"evidence\": \"ChIP, miR-200c 3'-UTR reporter, pathway over/knockdown, T-cell exhaustion assays, clinical correlation\",\n      \"pmids\": [\"29593314\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab axis\", \"In vivo causality of each node not fully separated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected SALL4 to metastatic and stemness programs in solid tumors through direct activation of TGF-β1 and a KHDRBS3–CD44 splicing axis.\",\n      \"evidence\": \"ChIP/reporter and TGF-β1 rescue (gastric); shRNA/overexpression with splicing isoform analysis (breast)\",\n      \"pmids\": [\"30349378\", \"29356399\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct ChIP at KHDRBS3 promoter\", \"Single-lab, context-specific findings\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed SALL4 sustains WNT/β-catenin-dependent neuromesodermal progenitors to control mesoderm-versus-neural fate during body elongation, integrating its developmental and signaling roles.\",\n      \"evidence\": \"Conditional TCre knockout, RNA-seq, SALL4 ChIP-seq, WNT reporters, embryonic phenotyping\",\n      \"pmids\": [\"31235634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct WNT-pathway target of SALL4 not pinpointed\", \"Mechanism of fate-balance control downstream of SALL4 unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked SALL4 to metabolic reprogramming by showing direct activation of glycolytic genes (HK-2) and feedback control of its own expression via the Brg1/miR-296-5p axis.\",\n      \"evidence\": \"ChIP/reporter with glycolysis assays and HK-2 rescue; Brg1 ChIP at SALL4 promoter with miRNA manipulation\",\n      \"pmids\": [\"32489324\", \"32320856\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab axes\", \"Direct versus indirect metabolic control not fully separated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Pinpointed the AT-rich binding zinc-finger cluster as the essential determinant of SALL4 genome occupancy and developmental function, and revealed a context where SALL4 restrains invasiveness via HDAC2.\",\n      \"evidence\": \"Genome-wide AT-binding screen, domain-specific mutagenesis with embryonic lethality, ChIP-seq/RNA-seq; melanoma KO with HDAC2 co-binding ChIP and HDAC-inhibitor epistasis\",\n      \"pmids\": [\"33406384\", \"34417458\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of AT recognition not solved\", \"How AT-content sensing selects which genes stay silenced unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined SALL4 as the indispensable NuRD-recruiting factor for chromatin closing during reprogramming and extended its activator role to angiogenic VEGF genes in cancer.\",\n      \"evidence\": \"ATAC-seq, Co-IP, N-terminal motif deletion and motif-grafting rescue in iPSC reprogramming; ChIP/EMSA/reporter and HUVEC assays for VEGF\",\n      \"pmids\": [\"37208322\", \"37525212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation of recruiting-NuRD vs NuRD-independent models across systems incomplete\", \"VEGF axis single-lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SALL4 toggles between NuRD-dependent repression and direct activation at individual loci, and the rules by which AT-rich enhancer binding is translated into context-specific gene programs, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified model reconciling NuRD-recruiting (37208322) and NuRD-independent (27471257) data\", \"Genome-scale determinants of activation versus repression undefined\", \"No structure of the AT-binding zinc-finger cluster on DNA\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 7, 14, 24, 30, 34]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [9, 0, 34]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 5, 26, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 9]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [9, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 7, 14]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [2, 4, 17, 18, 26, 33]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 13, 24, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 6, 7, 18, 27, 30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 24, 36]}\n    ],\n    \"complexes\": [\"Mi-2/NuRD\"],\n    \"partners\": [\"NANOG\", \"MLL\", \"DOT1L\", \"LSD1/KDM1A\", \"RARA\", \"PLZF\", \"HDAC2\", \"RBBP4\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}